Last reviewed · How we verify
Pegylated Liposomal Doxorubicin and Carboplatin
Pegylated Liposomal Doxorubicin and Carboplatin is a Small molecule drug developed by AGO Study Group. It is currently in Phase 2 development.
At a glance
| Generic name | Pegylated Liposomal Doxorubicin and Carboplatin |
|---|---|
| Sponsor | AGO Study Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
- Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE3)
- Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (PHASE1)
- A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer (PHASE2)
- QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated Liposomal Doxorubicin and Carboplatin CI brief — competitive landscape report
- Pegylated Liposomal Doxorubicin and Carboplatin updates RSS · CI watch RSS
- AGO Study Group portfolio CI
Frequently asked questions about Pegylated Liposomal Doxorubicin and Carboplatin
What is Pegylated Liposomal Doxorubicin and Carboplatin?
Pegylated Liposomal Doxorubicin and Carboplatin is a Small molecule drug developed by AGO Study Group.
Who makes Pegylated Liposomal Doxorubicin and Carboplatin?
Pegylated Liposomal Doxorubicin and Carboplatin is developed by AGO Study Group (see full AGO Study Group pipeline at /company/ago-study-group).
What development phase is Pegylated Liposomal Doxorubicin and Carboplatin in?
Pegylated Liposomal Doxorubicin and Carboplatin is in Phase 2.